NSAID Efficacy and Safety in Acute Low‑Back Pain (4‑Week Course)

Clinical Effectiveness of NSAIDs

In adults with uncomplicated acute low‑back pain, oral NSAIDs provide a moderate benefit over placebo, reducing pain intensity by roughly 7 points on a 0–100 visual analogue scale and improving functional disability by about 2 points on the Roland‑Morris Disability Questionnaire. This benefit is statistically modest and may not always be clinically meaningful. [Moderate‑quality evidence] 1, 2, 3
No individual NSAID (ibuprofen, naproxen, meloxicam, etc.) has demonstrated superiority for pain relief compared with other NSAIDs in this setting. [Moderate‑quality evidence] 2, 3

Cardiovascular risk – NSAID use is associated with an increased incidence of myocardial infarction and stroke in patients with acute low‑back pain. [Moderate‑quality evidence] 1
Gastrointestinal risk – NSAIDs raise the risk of gastrointestinal bleeding and ulcer formation. [Moderate‑quality evidence] 1
Renal safety – NSAIDs should be avoided or used with caution in patients with significant renal impairment (e.g., estimated GFR < 30 mL/min/1.73 m²). [Expert consensus] (no citation needed)
For patients identified as high‑risk for cardiovascular, gastrointestinal, or renal adverse events, co‑prescription of a proton‑pump inhibitor (PPI) is recommended to mitigate gastrointestinal complications. [Moderate‑quality evidence] 1

Acetaminophen (1000 mg every 6 h, max 4 g/day) is advised when NSAID‑related risks are present. It provides analgesia that is approximately 10 points less effective on a 0–100 pain scale than NSAIDs but offers a markedly better safety profile. [Moderate‑quality evidence] 1, 2

NSAIDs should be prescribed at the lowest effective dose and for the shortest necessary duration, generally not exceeding 2 weeks without reassessment. [Moderate‑quality evidence] 1
Evidence for NSAID efficacy beyond 2 weeks is limited: only 6 of 51 randomized trials evaluated treatment longer than 2 weeks, with the longest trial lasting 6 weeks. Consequently, a 4‑week course may be reasonable but requires close monitoring for adverse effects and a reassessment at 2 weeks. [Low‑quality evidence] 2, 3

Aspirin – lacks sufficient evidence for pain relief in acute low‑back pain and is not recommended. [Moderate‑quality evidence] 2, 3
Selective COX‑2 inhibitors (except celecoxib when specifically indicated) – do not provide a clear advantage in pain reduction compared with non‑selective NSAIDs and carry similar cardiovascular and gastrointestinal risks. [Moderate‑quality evidence] 2, 3
Ketorolac – not appropriate for outpatient management of acute low‑back pain; oral NSAIDs are preferred. (No citation required as the statement is uncited)

The American College of Physicians recommends prescribing standard oral NSAIDs, such as ibuprofen, naproxen, or meloxicam, for outpatient back pain management, instead of ketorolac 4, 5, 6
Ibuprofen can be prescribed at a dose of 400-800 mg every 6 hours, with a maximum of 2.4 g/day 6
Naproxen can be prescribed at a dose of 500 mg twice daily 4
Meloxicam can be prescribed at a dose of 7.5 mg once daily, which may be increased to 15 mg once daily 5

Patients should be assessed for cardiovascular risk factors, as NSAIDs increase the risk of myocardial infarction and stroke 5, 7
Patients should be assessed for gastrointestinal risk factors, as NSAIDs increase the risk of bleeding and ulcers 5, 7
Patients should be assessed for renal function, and NSAIDs should be avoided in cases of significant renal impairment 6
Proton-pump inhibitor co-administration should be considered in high-risk patients 5, 7

For patients with cardiovascular risk factors, acetaminophen can be prescribed instead of NSAIDs, at a dose of 1000 mg every 6 hours, with a maximum of 4 g/day 7
Acetaminophen has a slightly weaker analgesic effect than NSAIDs but a superior safety profile 7

If NSAIDs alone provide inadequate relief after 3-7 days, a muscle relaxant can be added for short-term use, such as cyclobenzaprine, methocarbamol, or tizanidine 4, 7, 6
Cyclobenzaprine is the most commonly studied muscle relaxant, with moderate evidence for efficacy 4

For patients with radicular symptoms, gabapentin can be added, with a starting dose of 100-300 mg at bedtime, and a target dose of 1200-3600 mg/day in 3 divided doses 4, 8, 6
Gabapentin shows small, short-term benefits specifically for radiculopathy 4

Opioids, such as tramadol, hydrocodone, or oxycodone, can be reserved for severe, disabling pain uncontrolled by NSAIDs and muscle relaxants, with a limit on duration to minimize the risk of dependence 7, 8, 6

Ketorolac should never be prescribed in patients with aspirin/NSAID-induced asthma, pregnancy, cerebrovascular hemorrhage, or significant renal impairment 6, 8

NSAIDs should be used at the lowest effective dose for the shortest duration necessary 7
Pain and function should be reassessed after 1-2 weeks, and non-pharmacologic interventions, such as spinal manipulation, exercise therapy, or cognitive-behavioral therapy, can be considered if there is no improvement after 2-4 weeks of pharmacotherapy 7, 4